Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BBIO BridgeBio Pharma	$51.18 +1.6%	$44.39	$21.72 ▼ $51.86	$9.78B	1.23	3.04 million shs	2.03 million shs
MRNA Moderna	$26.69 -0.7%	$29.18	$23.15 ▼ $91.99	$10.38B	1.83	10.81 million shs	5.79 million shs
VRNA Verona Pharma PLC American Depositary Share	$105.27 +0.1%	$98.45	$24.50 ▼ $105.50	$8.96B	0.12	2.29 million shs	1.30 million shs
XENE Xenon Pharmaceuticals	$37.96 +0.8%	$32.31	$26.74 ▼ $46.00	$2.93B	1.16	899,692 shs	784,656 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BBIO BridgeBio Pharma	+2.63%	+12.43%	+5.64%	+49.32%	+110.71%
MRNA Moderna	+4.79%	+0.67%	-18.19%	+13.70%	-67.56%
VRNA Verona Pharma PLC American Depositary Share	+0.01%	-0.18%	+0.51%	+51.30%	+293.57%
XENE Xenon Pharmaceuticals	+4.67%	+9.92%	+15.55%	+27.39%	-2.91%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BBIO BridgeBio Pharma	4.4793 of 5 stars	3.5	3.0	3.9	3.1	3.3	0.6
MRNA Moderna	4.3882 of 5 stars	4.0	1.0	4.6	2.9	2.5	0.6
VRNA Verona Pharma PLC American Depositary Share	1.9062 of 5 stars	2.1	3.0	0.0	3.2	2.5	0.6
XENE Xenon Pharmaceuticals	1.9797 of 5 stars	3.5	1.0	0.0	2.4	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BBIO BridgeBio Pharma	3.00	Buy	$61.35	19.88% Upside
MRNA Moderna	2.04	Hold	$43.59	63.31% Upside
VRNA Verona Pharma PLC American Depositary Share	2.15	Hold	$109.00	3.54% Upside
XENE Xenon Pharmaceuticals	3.00	Buy	$53.20	40.15% Upside

Current Analyst Ratings Breakdown

Latest XENE, MRNA, VRNA, and BBIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2025	XENE Xenon Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$55.00
8/12/2025	XENE Xenon Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$57.00 ➝ $55.00
8/12/2025	XENE Xenon Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$42.00 ➝ $43.00
8/6/2025	BBIO BridgeBio Pharma	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Outperform ➝ Sector Outperform	$55.00 ➝ $57.00
8/6/2025	BBIO BridgeBio Pharma	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$60.00 ➝ $61.00
8/4/2025	MRNA Moderna	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$40.00 ➝ $31.00
8/1/2025	MRNA Moderna	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$32.00
8/1/2025	MRNA Moderna	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$26.00
8/1/2025	MRNA Moderna	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$40.00
8/1/2025	MRNA Moderna	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Equal Weight ➝ Equal Weight	$32.00
7/30/2025	BBIO BridgeBio Pharma	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$56.00

(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BBIO BridgeBio Pharma	$221.90M	44.09	N/A	N/A	($9.30) per share	-5.50
MRNA Moderna	$3.24B	3.21	N/A	N/A	$24.16 per share	1.10
VRNA Verona Pharma PLC American Depositary Share	$42.28M	211.96	N/A	N/A	$3.27 per share	32.19
XENE Xenon Pharmaceuticals	$9.43M	310.40	N/A	N/A	$8.22 per share	4.62

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BBIO BridgeBio Pharma	-$535.76M	-$4.09	N/A	N/A	N/A	-329.25%	N/A	-85.69%	N/A
MRNA Moderna	-$3.56B	-$7.53	N/A	N/A	N/A	-94.31%	-25.96%	-20.09%	N/A
VRNA Verona Pharma PLC American Depositary Share	-$173.42M	-$0.99	N/A	3,509.00	N/A	-36.62%	-21.12%	-9.07%	8/14/2025 (Estimated)
XENE Xenon Pharmaceuticals	-$234.33M	-$3.55	N/A	N/A	N/A	N/A	-38.50%	-36.47%	N/A

Latest XENE, MRNA, VRNA, and BBIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	VRNA Verona Pharma PLC American Depositary Share	$0.39	N/A	N/A	N/A	$68.24 million	N/A
8/11/2025	Q2 2025	XENE Xenon Pharmaceuticals	-$1.03	-$1.07	-$0.04	-$1.07	N/A	N/A
8/6/2025	Q2 2025	VRNA Verona Pharma PLC American Depositary Share	-$0.01	$0.13	+$0.14	$0.13	$90.41 million	$103.14 million
8/5/2025	Q2 2025	BBIO BridgeBio Pharma	-$0.83	-$0.95	-$0.12	-$0.95	$98.46 million	$110.57 million
8/1/2025	Q2 2025	MRNA Moderna	-$2.99	-$2.13	+$0.86	-$2.13	$116.26 million	$142.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BBIO BridgeBio Pharma	N/A	N/A	N/A	N/A	N/A
MRNA Moderna	N/A	N/A	N/A	N/A	N/A
VRNA Verona Pharma PLC American Depositary Share	N/A	N/A	N/A	N/A	N/A
XENE Xenon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BBIO BridgeBio Pharma	N/A	5.19	5.08
MRNA Moderna	N/A	3.93	3.77
VRNA Verona Pharma PLC American Depositary Share	0.87	10.71	10.54
XENE Xenon Pharmaceuticals	N/A	17.66	17.66

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BBIO BridgeBio Pharma	99.85%
MRNA Moderna	75.33%
VRNA Verona Pharma PLC American Depositary Share	85.88%
XENE Xenon Pharmaceuticals	95.45%

Insider Ownership

Company	Insider Ownership
BBIO BridgeBio Pharma	18.20%
MRNA Moderna	11.00%
VRNA Verona Pharma PLC American Depositary Share	4.80%
XENE Xenon Pharmaceuticals	4.07%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BBIO BridgeBio Pharma	400	191.17 million	156.38 million	Optionable
MRNA Moderna	5,800	389.08 million	346.28 million	Optionable
VRNA Verona Pharma PLC American Depositary Share	30	85.13 million	81.05 million	Optionable
XENE Xenon Pharmaceuticals	210	77.11 million	73.61 million	Optionable

XENE, MRNA, VRNA, and BBIO Headlines

Recent News About These Companies

Xenon Pharmaceuticals' (XENE) "Buy" Rating Reiterated at Chardan Capital

2 hours ago | marketbeat.com

Chardan Capital Reiterates Buy Rating for Xenon Pharmaceuticals (NASDAQ:XENE)

August 14 at 2:13 AM | americanbankingnews.com

Xenon Pharmaceuticals (NASDAQ:XENE) Shares Gap Up After Analyst Upgrade

August 13 at 10:52 AM | marketbeat.com

Royal Bank Of Canada Has Lowered Expectations for Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price

August 13 at 10:25 AM | marketbeat.com

Xenon Pharmaceuticals (NASDAQ:XENE) Given New $43.00 Price Target at Wedbush

August 13 at 9:40 AM | marketbeat.com

Wedbush Issues Positive Forecast for Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price

August 13 at 3:31 AM | americanbankingnews.com

TD Cowen Reaffirms Their Buy Rating on Xenon (XENE)

August 13 at 2:39 AM | theglobeandmail.com

Xenon Completes Patient Recruitment for Phase 3 Study

August 13 at 2:39 AM | theglobeandmail.com

Xenon Pharmaceuticals (NASDAQ:XENE) Announces Quarterly Earnings Results

August 12 at 9:25 PM | marketbeat.com

Xenon Pharmaceuticals price target lowered to $55 from $57 at RBC Capital

August 12 at 8:39 PM | msn.com

Xenon Pharmaceuticals: Pushing Azetukalner Towards Finish Line With Phase 3 2026 Data Release

August 12 at 3:05 PM | seekingalpha.com

Xenon Q2 Loss Wider Than Expected, Pipeline Development in Focus

August 12 at 11:21 AM | zacks.com

Xenon Pharmaceuticals Reports Q2 2025 Progress and Outlook

August 12 at 3:55 AM | msn.com

Xenon Pharmaceuticals Inc. (XENE) Q2 2025 Earnings Call Transcript

August 11 at 12:03 AM | seekingalpha.com

Xenon Pharmaceuticals: Q2 Earnings Snapshot

August 11 at 10:54 PM | chron.com

Xenon Pharmaceuticals jumps after massive earnings beat

August 11 at 5:54 PM | investing.com

Xenon Reports Second Quarter 2025 Financial Results & Business Update

August 11 at 4:01 PM | globenewswire.com

Mutual of America Capital Management LLC Acquires Shares of 48,763 Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

August 11 at 4:51 AM | marketbeat.com

Xenon Pharma Q2 2025 Earnings Preview

August 11 at 2:52 AM | seekingalpha.com

2XENE : A Look Ahead: Xenon Pharmaceuticals's Earnings Forecast

August 8, 2025 | benzinga.com

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives $54.82 Consensus PT from Brokerages

August 7, 2025 | americanbankingnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

XENE, MRNA, VRNA, and BBIO Company Descriptions

BridgeBio Pharma NASDAQ:BBIO

$51.18 +0.80 (+1.59%)

Closing price 04:00 PM Eastern

Extended Trading

$51.25 +0.07 (+0.14%)

As of 06:14 PM Eastern

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Moderna NASDAQ:MRNA

$26.69 -0.20 (-0.74%)

Closing price 04:00 PM Eastern

Extended Trading

$26.64 -0.05 (-0.21%)

As of 07:02 PM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Verona Pharma PLC American Depositary Share NASDAQ:VRNA

$105.27 +0.07 (+0.07%)

Closing price 04:00 PM Eastern

Extended Trading

$105.30 +0.03 (+0.03%)

As of 06:25 PM Eastern

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.

Xenon Pharmaceuticals NASDAQ:XENE

$37.96 +0.29 (+0.77%)

Closing price 04:00 PM Eastern

Extended Trading

$38.03 +0.07 (+0.20%)

As of 06:37 PM Eastern

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time